Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Authors
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Alireza Atri, Susan L Mills, Anna M Santacruz, Guoqiao Wang, Charlene Supnet, Tammie L S Benzinger, Brian A Gordon, Laura Ibanez, Gregory Klein, Monika Baudler, Rachelle S Doody, Paul Delmar, Geoffrey A Kerchner, Tobias Bittner, Jakub Wojtowicz, Azad Bonni, Paulo Fontoura, Carsten Hofmann, Luka Kulic, Jason Hassenstab, Andrew J Aschenbrenner, Richard J Perrin, Carlos Cruchaga, Alan E Renton, Chengjie Xiong, Alison A Goate, John C Morris, David M Holtzman, B Joy Snider, Catherine Mummery, William S Brooks, David Wallon, Sarah B Berman, Erik Roberson, Colin L Masters, Douglas R Galasko, Suman Jayadev, Rachel Sanchez-Valle, Jeremie Pariente, Justin Kinsella, Christopher H van Dyck, Serge Gauthier, Ging-Yuek Robin Hsiung, Mario Masellis, Bruno Dubois, Lawrence S Honig, Clifford R Jack, Alisha Daniels, David Aguillón, Ricardo Allegri, Jasmeer Chhatwal, Gregory Day, Nick C Fox, Edward Huey, Takeshi Ikeuchi, Mathias Jucker, Jae-Hong Lee, Allan I Levey, Johannes Levin, Francisco Lopera, JeeHoon Roh, Pedro Rosa-Neto, Peter R Schofield, Dominantly Inherited Alzheimer's Disease–Trials Unit